Journal
VIRUSES-BASEL
Volume 13, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/v13020338
Keywords
herpesvirus; herpes simplex virus; genome editing; homing endonuclease; CRISPR; Cas9
Categories
Funding
- Haas Scholars Fellowship Program
Ask authors/readers for more resources
Herpes simplex virus 1 (HSV-1) can cause cold sores or keratitis in healthy individuals, but severe complications in immune-compromised or neonatal patients. Current therapies can block viral replication but have limited effect on viral latency, necessitating the development of new strategies. Genome editing methods like homing endonucleases and CRISPR/Cas systems show promise in inhibiting HSV-1 infection.
Herpes simplex virus 1 (HSV-1) is a herpesvirus that may cause cold sores or keratitis in healthy or immunocompetent individuals, but can lead to severe and potentially life-threatening complications in immune-immature individuals, such as neonates or immune-compromised patients. Like all other herpesviruses, HSV-1 can engage in lytic infection as well as establish latent infection. Current anti-HSV-1 therapies effectively block viral replication and infection. However, they have little effect on viral latency and cannot completely eliminate viral infection. These issues, along with the emergence of drug-resistant viral strains, pose a need to develop new compounds and novel strategies for the treatment of HSV-1 infection. Genome editing methods represent a promising approach against viral infection by modifying or destroying the genetic material of human viruses. These editing methods include homing endonucleases (HE) and the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated protein (Cas) RNA-guided nuclease system. Recent studies have showed that both HE and CRISPR/Cas systems are effective in inhibiting HSV-1 infection in cultured cells in vitro and in mice in vivo. This review, which focuses on recently published progress, suggests that genome editing approaches could be used for eliminating HSV-1 latent and lytic infection and for treating HSV-1 associated diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available